| 纯度 | >80%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RPL35 |
| Uniprot No | P42766 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-123aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMAKIKAR DLRGKKKEEL LKQLDDLKVE LSQLRVAKVT GGAASKLSKI RVVRKSIARV LTVINQTQKE NLRKFYKGKK YKPLDLRPKK TRAMRRRLNK HEENLKTKKQ QRKERLYPLR KYAVKA |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RPL35重组蛋白的3篇参考文献的简要总结：
1. **文献名称**: "RPL35 as a novel prognostic biomarker in colorectal cancer: association with tumor progression and survival"
**作者**: Li, X. et al.
**摘要**: 该研究通过重组表达RPL35蛋白，发现其在结直肠癌组织中高表达，且与患者预后不良显著相关。体外实验表明，RPL35通过调控核糖体生物合成促进癌细胞增殖和转移。
2. **文献名称**: "Recombinant human RPL35 protein production and its role in ribosome assembly"
**作者**: Zhang, Y. et al.
**摘要**: 研究利用大肠杆菌系统成功表达并纯化重组人源RPL35蛋白，证明其参与核糖体大亚基的组装过程，并解析了其与rRNA结合的分子机制。
3. **文献名称**: "Structural characterization of RPL35 and its interaction with chemotherapeutic agents"
**作者**: Wang, H. et al.
**摘要**: 通过重组RPL35蛋白的晶体结构分析，揭示了其与抗癌药物(如阿霉素)的潜在结合位点，为靶向核糖体蛋白的肿瘤治疗策略提供了结构基础。
注：以上文献信息为示例，实际文献需通过数据库(如PubMed、Web of Science)检索确认。若需具体论文，建议补充研究关键词(如疾病方向或功能机制)。
**Background of RPL35 Recombinant Protein**
RPL35 (Ribosomal Protein L35) is a component of the 60S ribosomal subunit, playing a critical role in protein synthesis by facilitating ribosome assembly and translation efficiency. As part of the ribosomal machinery, it contributes to the structural stability of the ribosome and ensures accurate decoding of mRNA into polypeptide chains. Dysregulation of RPL35 has been linked to various cellular dysfunctions, including impaired proliferation, developmental defects, and diseases such as cancer, where its overexpression or mutations may influence tumor progression.
Recombinant RPL35 protein is engineered using genetic engineering techniques, typically expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian or insect cells) to ensure proper folding and post-translational modifications. The purified protein retains biological activity, enabling its use in functional studies, such as investigating ribosome biogenesis, translation mechanisms, or interactions with other ribosomal proteins and nucleic acids.
Research applications of RPL35 recombinant protein include *in vitro* binding assays, structural analysis (e.g., X-ray crystallography or cryo-EM), and cellular studies to explore its role in diseases. It also serves as a tool for developing targeted therapies, such as inhibitors disrupting ribosome function in cancer cells. Additionally, antibodies generated against recombinant RPL35 aid in diagnostic assays to quantify protein expression in clinical samples.
The study of RPL35 recombinant protein bridges fundamental ribosome biology with translational medicine, offering insights into both cellular homeostasis and pathogenic mechanisms, while supporting drug discovery and biomarker development.
×
